On November 13, Hinge Health, Inc. fell 4.19% in Regular Trading, trading at $115.705 per share, with turnover of $14.4595 million.
The latest catalyst was an insider transaction disclosure showing Chief Financial Officer James Budge sold 35,907 Class A common shares on November 10 for about $4.37 million, at prices ranging from $119.5214 to $123.3433 per share. After the sale, he still directly held 256,207 shares, but the disclosure nevertheless appeared to pressure near-term market sentiment.
The pullback comes even though Hinge Health, Inc. recently reported better-than-expected third-quarter results, with adjusted earnings and revenue above consensus and full-year revenue guidance raised to $879 million to $881 million. Analysts also lifted price targets after the report, including RBC to $135 while maintaining an Outperform rating, underscoring that the current weakness is more closely tied to the latest insider-sale filing than to operating fundamentals.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments